JS001+IMP4297 in Patients With Advanced Cancer

Summary

This is a Phase I/Ib open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of toripalimab in combination with senaparib in patients with advanced solid tumors. The study consists of 2 parts, the Phase I part of the study will be a dose-escalation evaluation to determine the RP2D of senaparib to be administered in combination with the fixed dose of toripalimab, and the Phase Ib portion will further evaluate the RP2D and evaluate the efficacy of combination in specific types of advanced solid tumors.

Timeline

Start

2022-03-29

Primary completion

2024-04-06

Completion

2024-06-06

Outcome

Outcome not reported

Stopped: “The sponsor voluntarily terminated the study before it was initiated”

Drugs

Indications